WARPTECHNEWS · LAB

Home AI Business Tech Archive

Storia: This LSD-Based Drug Just Scored Again; Stock Soars — Warptech Lab News

Storia in 6 fonti

This LSD-Based Drug Just Scored Again; Stock Soars

Definium Therapeutics unveiled the second of two positive Phase 3 studies for its LSD-based drug. The biotech stock surged on the results.

Raccontata da

biopharmadive.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

investors.comStai leggendo1 g fa

This LSD-Based Drug Just Scored Again; Stock Soars

Definium Therapeutics unveiled the second of two positive Phase 3 studies for its LSD-based drug. The biotech stock surged on the results.

Timeline cronologica

mercoledì 12 agosto 2026·biopharmadive.com
Psychedelics developer Definium scores more positive data for LSD pill
Results from a late-stage study focused on generalized anxiety disorder were a “clean win” to analysts, who believe Definium has a drug with multibillion-dollar sales potential.
mercoledì 12 agosto 2026·endpoints.news
Definium's LSD drug clears bar in first of two Phase 3 anxiety disorder trials
Definium Therapeutics oral LSD candidate DT120 has passed a late-stage study in generalized anxiety disorder (GAD), not even two months after reporting trial success for in…

biopharmadive.com

1 g fa

Psychedelics developer Definium scores more positive data for LSD pill

Results from a late-stage study focused on generalized anxiety disorder were a “clean win” to analysts, who believe Definium has a drug with multibillion-dollar sales potential.

Leggi questa versione → originale

endpoints.news1 g fa

Definium's LSD drug clears bar in first of two Phase 3 anxiety disorder trials

Definium Therapeutics oral LSD candidate DT120 has passed a late-stage study in generalized anxiety disorder (GAD), not even two months after reporting trial success for in depression.

Leggi questa versione → originale

statnews.com1 g fa

Definium Therapeutics says its LSD therapy eased anxiety in late-stage trial

Definium Therapeutics said that its LSD therapy significantly helped patients with generalized anxiety disorder in the first of two large trials.

Leggi questa versione → originale

gizmodo.com1 g fa

LSD Just Passed Its Biggest Trial Yet for Anxiety

It's the second major victory this year for Definium Therapeutics and its proprietary version of LSD.

Leggi questa versione → originale

thehindu.com7 h fa

Definium says LSD-based pill reduces anxiety in late-stage study

Definium's LSD-based pill significantly reduces anxiety in a late-stage study, boosting shares over 20% amid promising results.

Leggi questa versione → originale

mercoledì 12 agosto 2026·

statnews.com

Definium Therapeutics says its LSD therapy eased anxiety in late-stage trial

Definium Therapeutics said that its LSD therapy significantly helped patients with generalized anxiety disorder in the first of two large trials.

mercoledì 12 agosto 2026·

investors.com

This LSD-Based Drug Just Scored Again; Stock Soars

Definium Therapeutics unveiled the second of two positive Phase 3 studies for its LSD-based drug. The biotech stock surged on the results.

mercoledì 12 agosto 2026·

gizmodo.com

LSD Just Passed Its Biggest Trial Yet for Anxiety

It's the second major victory this year for Definium Therapeutics and its proprietary version of LSD.

giovedì 13 agosto 2026·

thehindu.com

Definium says LSD-based pill reduces anxiety in late-stage study

Definium's LSD-based pill significantly reduces anxiety in a late-stage study, boosting shares over 20% amid promising results.

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com